Protalix BioTherapeutics, Inc. (PLX)

Market Cap	83.95M
Revenue (ttm)	59.65M
Net Income (ttm)	6.85M
Shares Out	73.32M
EPS (ttm)	0.04
PE Ratio	28.50
Forward PE	19.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,494
Open	1.160
Previous Close	1.170
Day's Range	1.130 - 1.160
52-Week Range	1.030 - 2.510
Beta	0.90
Analysts	Strong Buy
Price Target	10.00 (+777.19%)
Earnings Date	May 10, 2024

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recomb...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 208
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX

Analyst Forecast

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(777.19% upside)

Analyst Consensus: Strong Buy